WT1 and cancer: Consequently, we and others have demonstrated the clinical utility of WT1-targeted immunotherapies in multiple forms, including a WT1 peptide cancer vaccine [20,21,22,23], WT1 peptide-pulsed dendritic cell vaccine [24], or WT1 mRNA-electroporated dendritic cell vaccine [25], as well as WT1-specific T cell receptor-transduced T-cell therapy [26,27].